"In preclinical studies, we see that the tumour — melanoma — simply dissolves, disappears, and not only the tumour itself, but even metastasis disappears," Gintsburg said. "I do not rule out that we will have patients at stage 4."
He said there were currently plans to begin testing the vaccine in lung, kidney and pancreatic cancer cases.
Oncology institutes are planned to be involved in this work, Gintsburg explained.
The research chief told Sputnik that the cancer vaccine would be tailored to each patient individually.
Artificial intelligence will help in its development, which will analyse the parameters of the tumour and draw up a "blueprint" for the bespoke treatment. Specialists would produce a vaccine based on that data within a week.